一種新型軟件模塊為放射科醫生提供了一種血管分析系統，能夠有效評估對比增強計算機X線斷層血管成像術和核磁共振檢查評估血管狹窄、支架和支架放置計劃、以及支架放置監測。

這種三維VesselMetrix模塊是由Barco公司開發的，最近剛剛獲得美國食品藥品管理局的許可。Voxar產品小組總經理Craig Anderson指出："VesselMetirx得到了我們客戶和PACS(圖像存檔和通信系統)合作伙伴的認可，因為它易于操作，工作穩定可靠。它使得放射科醫生在閱讀血管成像資料的時候，對質量和效率制定新的標準。"

他說："我們的客戶和PACS合作伙伴需要三維臨床應用軟件，要求用戶界面友好并能夠提高工作效率。VeslMetrix滿足了血管成像研究的要求，達到了我們為放射科醫生提供他們所需要的能夠有效閱讀龐大的測定容量數據研究的基本要求。"
 
Software for 3D Vessel Analysis
 
A new software module provides radiologists with a vessel analysis system to effectively assess contrast-enhanced computed tomography angiography (CTA) and magnetic resonance angiography (MRA) studies for evaluating stenosis, stent and stent graft planning, and stent graft monitoring.

The 3D (three-dimensional) VesselMetrix module, developed by Barco (Kortrijk, Belgium), has just been cleared by the U.S. Food and Drug Administration (FDA). “VesselMetrix was very well received by our customers and PACS [picture archiving and communications system] partners because of its ease-of-use and incredibly fast performance. It allows radiologists to set new standards in quality and efficiency when reading angiographic studies,” stated Craig Anderson, general manager of the Voxar product group.

“Our customers and PACS partners need 3D-enabled clinical software applications that are user-friendly and optimized to increase productivity. VeselMetrix delivers this for angiographic studies and is fundamental to our goal of providing radiologists with the tools they need to effectively read large volumetric data studies,” he added.